<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl3">
 <label>Table 3</label>
 <caption>
  <p>Representative Practical Well-designed Clinical Trials of Emerging COVID-19 Therapies</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Trial</th>
    <th>Geography (target enrollment)</th>
    <th>Sponsor</th>
    <th>Therapeutic focus</th>
    <th>Control</th>
    <th>Study design/characteristics</th>
    <th>Inclusion/exclusion criteria</th>
    <th>Selected outcomes</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>SOLIDARITY
     <xref rid="bib120" ref-type="bibr">
      <sup>120</sup>
     </xref>
    </td>
    <td>Global</td>
    <td>World Health Organization</td>
    <td>SoC + remdesivir
     <break/>SoC + CQ/HCQ
     <break/>SoC + LPV/RTV
     <break/>SoC + LPV/RTV + IFN β-1a
    </td>
    <td>SoC</td>
    <td>Phase III, adaptive, open-label RCT</td>
    <td>≥18 y and hospitalized with confirmed COVID-19</td>
    <td>Mortality
     <break/>Hospital length of stay
     <break/>Receipt of ventilation or intensive care
    </td>
   </tr>
   <tr>
    <td>Trial of Treatments for COVID-19 in Hospitalized Adults (DisCoVeRy) (ClinicalTrials.gov identifier: 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04315948" id="intref0150" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04315948</ext-link>)
    </td>
    <td>Europe (3100)</td>
    <td>Inserm</td>
    <td>SoC + remdesivir
     <break/>SoC + LPV/RTV
     <break/>SoC + IFN β-1a
     <break/>SoC + HCQ
    </td>
    <td>SoC</td>
    <td>Phase III multicenter/country, adaptive, open-label RCT</td>
    <td>≥18 y and hospitalized with confirmed COVID-19 + SpO
     <sub>2</sub> ≤94% or acute respiratory failure
    </td>
    <td>Clinical status at day 15
     <break/>Hospital length of stay
     <break/>Mortality
    </td>
   </tr>
   <tr>
    <td>Randomised Evaluation of COVID-19 therapy (RECOVERY) Trial (International Clinical trials Registry Platform identifier: ISRCTN50189673)</td>
    <td>United Kingdom (5000)</td>
    <td>University of Oxford</td>
    <td>SoC + LPV/RTV
     <break/>SoC + IFN β-1a
     <break/>SoC + HCQ
     <break/>SoC + dexamethasone
    </td>
    <td>SoC</td>
    <td>Phase II/III, adaptive, open-label RCT</td>
    <td>≥18 y and hospitalized with confirmed COVID-19</td>
    <td>Mortality within 28 d of randomization
     <break/>Hospital length of stay
     <break/>Number of patients needing ventilation
    </td>
   </tr>
   <tr>
    <td>Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease (HYCOVID) (ClinicalTrials.gov identifier: 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04325893" id="intref0155" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04325893</ext-link>)
    </td>
    <td>France (1300)</td>
    <td>University Hospital Angers</td>
    <td>HCQ</td>
    <td>Placebo</td>
    <td>Phase III, multicenter, double-blind RCT</td>
    <td>≥18 y with COVID-19 diagnosed within previous 48 h + ≥75 y or SpO
     <sub>2</sub> ≤94% or FiO
     <sub>2</sub> ≤300 mm Hg
     <break/>Electrocardiogram showing the absence of QT interval prolongation
    </td>
    <td>Mortality or need for intubation and mechanical ventilation within 14 d of inclusion and initiation of treatment
     <break/>Clinical improvement at 14 and 28 d
    </td>
   </tr>
   <tr>
    <td>Adaptive COVID-19 Treatment Trial (ACTT) (ClinicalTrials.gov identifier: 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04280705" id="intref0160" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04280705</ext-link>)
    </td>
    <td>Global (440)</td>
    <td>National Institute of Allergy and Infectious Diseases</td>
    <td>Remdesivir</td>
    <td>Placebo</td>
    <td>Phase III, multicenter, adaptive, double-blind RCT</td>
    <td>≥18 y with COVID-19 diagnosed within previous 72 h + radiographic infiltrates by imaging or SpO
     <sub>2</sub> ≤94% or requiring supplemental oxygen or requiring mechanical ventilation
    </td>
    <td>Percentage of participants reporting each severity rating on an 8-point ordinal scale at day 15
     <break/>Hospital length of stay
     <break/>14- and 28-d mortality
    </td>
   </tr>
   <tr>
    <td>A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia (COVACTA) (ClinicalTrials.gov identifier: 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04320615" id="intref0165" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04320615</ext-link>)
    </td>
    <td>Global (330)</td>
    <td>Hoffmann-La Roche</td>
    <td>Tocilizumab</td>
    <td>Placebo</td>
    <td>Phase III, multicenter, double-blind RCT</td>
    <td>≥18 y and hospitalized with confirmed COVID-19 + SpO
     <sub>2</sub> ≤93% or PaO
     <sub>2</sub> &lt;300 mm Hg
    </td>
    <td>Clinical status assessed with a 7-point ordinal scale at day 28
     <break/>Incidence of mechanical ventilation
     <break/>7, 14, 21, 28, and 60-d mortality
    </td>
   </tr>
   <tr>
    <td>Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) (ClinicalTrials.gov identifier: 
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04342182" id="intref0170" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04342182</ext-link>)
    </td>
    <td>The Netherlands (426)</td>
    <td>Erasmus Medical Center</td>
    <td>COVID-19 convalescent plasma</td>
    <td>SoC</td>
    <td>Phase II/III, randomized single-blind, comparative trial</td>
    <td>≥18 y and hospitalized with confirmed COVID-19, excluding patients with a “no ICU admission” or “no invasive ventilation” restriction</td>
    <td>Overall mortality until hospital discharge or 60-d
     <break/>Hospital length of stay
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>COVID-19 = coronavirus disease 2019; CQ/HCQ = chloroquine or hydroxychloroquine; FiO
    <sub>2</sub> = fraction of inspired oxygen; ICU = intensive care unit; IFN = interferon; LPV/RTV = lopinavir/ritonavir; PaO
    <sub>2</sub> = partial pressure of oxygen; RCT = randomized controlled trial; SoC = standard of care; SpO
    <sub>2</sub> = peripheral capillary oxygen saturation.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
